Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

COMy Virtual 2020 | COMy 2020 – what can we look forward to?

Artur Jurczyszyn • 11 May 2020
COMy Virtual 2020
Multiple Myeloma Antibodies Belantamab mafodotin CAR-T

Artur Jurczyszyn, MD, PhD, Jagiellonian University Medical College, Kraków, Poland, highlights the data he’s looking forward to hearing at COMy 2020. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Artur Jurczyszyn

2:20
Aims & projects of the Myeloma Treatment Foundation Centre in Poland
Artur Jurczyszyn • 26 Aug 2022
1:21
The impact of physical activity in patients with multiple myeloma
Artur Jurczyszyn • 26 Aug 2022
1:25
The importance of early treatment in MGRS & the role of the MDT
Artur Jurczyszyn • 26 Aug 2022
1:13
The importance of bone disease control in multiple myeloma
Artur Jurczyszyn • 26 Aug 2022

Related Videos

4:59
MRD as an endpoint for accelerating drug approval in multiple myeloma: updates from the ODAC meeting
Ola Landgren • 13 Apr 2024
1:47
Looking forward to the Miami Myeloma MRD Virtual Meeting 2024
Ola Landgren • 13 Apr 2024
2:27
The encouraging results of the LINKER-MM1 trial: safety and efficacy of linvoseltamab in R/R myeloma
Faith Davies • 9 Apr 2024
0:37
Upcoming studies investigating linvoseltamab in myeloma
Faith Davies • 9 Apr 2024
The content of VJHemOnc is intended for healthcare professionals